Gemini

Gemini is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) developed by Revelation Biosciences. It is designed to reduce inflammation-associated damage by reprogramming the innate immune system to respond in a less damaging manner to stressors such as trauma or infection. Gemini has demonstrated pharmacodynamic activity in clinical studies, including upregulation of anti-inflammatory cytokines like IL-10 and reduction of proinflammatory cytokines. It is being developed for multiple indications, including prevention or reduction of acute kidney injury (GEMINI-AKI program), prevention or reduction of post-surgical infection (GEMINI-PSI program), and treatment to slow the progression of chronic kidney disease (GEMINI-CKD program).

Brand names

REVTx-300REVTx300REVTx 300

Other names

Synthetic monophosphoryl Lipid A